Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Sephy Philip, Sumita Chowdhury, John R. Nelson, P. Benjamin Everett, Carolyn K. Hulme-Lowe & Jordana K. Schmier. (2016) A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States. Journal of Medical Economics 19:10, pages 1003-1010.
Read now
Read now
James M. McKenney. (2012) Combination Treatment with Atorvastatin plus Niacin Provides Effective Control of Complex Dyslipidemias: A Literature Review. Postgraduate Medicine 124:1, pages 7-20.
Read now
Read now
JoAnne M. Foody, Phillip M. Mendys, Larry Z. Liu & Ross J. Simpson$suffix/text()$suffix/text(). (2010) The Utility of Observational Studies in Clinical Decision Making: Lessons Learned from Statin Trials. Postgraduate Medicine 122:3, pages 222-229.
Read now
Read now
Edith M. Heintjes, Fernie J.A. Penning-van Beest, Saga Johansson, Anton F. Stalenhoef & Ron M.C. Herings. (2009) Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. Current Medical Research and Opinion 25:11, pages 2621-2629.
Read now
Read now
Dan Atar, Rafael Carmena, Peter Clemmensen, Annik K-Laflamme, Sven Wassmann, Peter Lansberg & Richard Hobbs. (2009) Clinical review: Impact of statin substitution policies on patient outcomes. Annals of Medicine 41:4, pages 242-256.
Read now
Read now
Richard J. Willke, Steve Zhou & Robert A. Vogel. (2008) Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience. Current Medical Research and Opinion 24:10, pages 2873-2882.
Read now
Read now
Articles from other publishers (10)
Uchenna Anyanwagu, Jil Mamza, Richard Donnelly & Iskandar Idris. (2017) Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Dan Atar, Seleen Ong & Peter J Lansberg. (2015) Expanding the Evidence Base. American Journal of Therapeutics 22:5, pages e141-e150.
Crossref
Crossref
Anke Neumann, Géric Maura, Alain Weill, Philippe Ricordeau, François Alla & Hubert Allemand. (2013) Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. Pharmacoepidemiology and Drug Safety 23:3, pages 240-250.
Crossref
Crossref
Ross J Simpson, James Signorovitch, Karthik Ramakrishnan, Jasmina Ivanova, Howard Birnbaum & Andreas Kuznik. (2011) Cardiovascular and Economic Outcomes After Initiation of Atorvastatin versus Simvastatin in an Employed Population Stratified by Cardiovascular Risk. American Journal of Therapeutics 18:6, pages 436-448.
Crossref
Crossref
Saske Hoving, Sylvia Heeneman, Marion J.J. Gijbels, Johannes A.M. te Poele, Jeffrey F.C. Pol, Karen Gabriels, Nicola S. Russell, Mat J.A.P. Daemen & Fiona A. Stewart. (2011) Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice. Radiotherapy and Oncology 101:1, pages 100-108.
Crossref
Crossref
T. Sathyapalan, S. L. Atkin & E. S. Kilpatrick. (2010) Low density lipoprotein‐cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?. Diabetes, Obesity and Metabolism 12:6, pages 540-544.
Crossref
Crossref
Ross J. SimpsonJrJr, James Signorovitch, Howard Birnbaum, Jasmina Ivanova, Cristina Connolly, Yohanne Kidolezi & Andreas Kuznik. (2009) Cardiovascular and Economic Outcomes After Initiation of Lipid-Lowering Therapy With Atorvastatin vs Simvastatin in an Employed Population. Mayo Clinic Proceedings 84:12, pages 1065-1072.
Crossref
Crossref
Stephen P. Motsko, Stefan Russmann, Eileen E. Ming, Varinder P. Singh, Ruby M. Vendiola & Judith K. Jones. (2009) Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events—a cohort study in 395 039 patients from clinical practice. Pharmacoepidemiology and Drug Safety 18:12, pages 1214-1222.
Crossref
Crossref
Terry A. Jacobson, Debra A. Wertz, Tracey Hoy, Andreas Kuznik, Daniel Grochulski & Mark Cziraky. (2008) Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated. Mayo Clinic Proceedings 83:12, pages 1316-1325.
Crossref
Crossref
JoAnne M. Foody, Amie T. Joyce, Amy E. Rudolph, Larry Z. Liu & Joshua S. Benner. (2008) Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: A large database analysis of managed care plans in the United States. Clinical Therapeutics 30:1, pages 195-205.
Crossref
Crossref